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Abstract The American Cancer Society (ACS) recom-
mends at least 150 min of moderate intensity physical
activity per week, alcohol intake of B1 drink per day, and
maintaining a body mass index (BMI) of \25 kg/m2 for
breast cancer prevention. Adherence to these guidelines has
been linked to lower overall mortality in average-risk
populations, it is not known if mortality reduction extends
to women at higher risk given their family history of breast
cancer. We followed 2,905 women from a high-risk Breast
Cancer Family Registry in New York, of which 77 % were
white non-Hispanic and 23 % were Hispanic. We collected
information on BMI, physical activity, and alcohol intake
at baseline and prospectively followed our cohort for out-
comes based on questionnaires and National Death Index
linkage. We used Cox regression to examine the relation
between adherence to ACS guidelines and overall mortality
and examined effect modification by race, age, and BRCA
status. There were 312 deaths after an average of
9.2 ± 4.1 years of follow-up. Adherence to all three ACS
recommendations was associated with 44–53 % lower
mortality in women unaffected with breast cancer at
baseline [Hazard Ratio (HR) 0.56, 95 % CI (0.33–0.93)]
and in women affected with breast cancer at baseline [HR
0.47, 95 % CI (0.30–0.74)]. These associations remained
after stratification by age, race, and BRCA status {e.g.,
BRCA1 and/or BRCA2 carriers [HR 0.39, 95 % CI
(0.16–0.97)]}. These results support that women at high
risk, similar to women at average risk, may also have
substantial benefits from maintaining the ACS guidelines.
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Introduction
The American Cancer Society (ACS) recommends health
guidelines for breast cancer prevention that include life-
style behaviors for regular physical activity, moderate
alcohol consumption, and maintaining a healthy body mass
index (BMI) [1]. The current recommendations for women
are as follows: (1) ‘‘to be as lean as possible throughout life
without being underweight’’; (2) ‘‘to get at least 150 min of
moderate intensity or 75 min of vigorous intensity activity
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each week (or a combination of these) preferably spread
throughout the week’’; and (3) ‘‘to drink no more than one
drink per day’’ [1].
Epidemiological studies have provided evidence that
individuals who adhere to these ACS guidelines and other
similar health guidelines on physical activity, alcohol
consumption, and body size have better health outcomes
including reduced risk of chronic disease, including dia-
betes, myocardial infarction, stroke, and cancer [2] as well
as reduced mortality [3–5]. For example, recent results
from a large European cohort consisting of nearly 400,000
participants from the World Cancer Research Fund/
American Institute for Cancer Research indicate that there
is an 18 % reduction in incidence of total cancers [6] and a
34 % reduction in mortality when comparing those in the
highest group of adherence to the lowest group [7]. Simi-
larly, in the U.S. in an ACS cohort of 100,000 men and
women from 21 different states with population-based
cancer registries, those who adhered to ACS cancer pre-
vention guidelines had a 42 % reduction in all-cause
mortality and a 24 % reduction in cancer-specific mortality
[8]. In addition to mortality reductions, adherence to ACS
guidelines has also been associated with lower cancer
incidence. For example, in a cohort of over 93,000 post-
menopausal women enrolled from 40 U.S. clinical centers,
adherence to ACS cancer prevention guidelines was asso-
ciated with a 22 % reduction in the incidence of breast
cancer, a 52 % reduction of colorectal cancer incidence,
and a 27 % reduction in endometrial cancer incidence [9].
Women who adhered to cancer prevention guidelines had a
27 % reduction in all-cause mortality, a 61 % lower risk of
colorectal cancer death, and a 33 % lower risk of death
from breast cancer [9].
These cohorts suggest a large unrealized potential for
cancer prevention in populations at average risk of cancer.
Family history of cancer dramatically increases risk of most
cancers including breast cancer, of which only a portion is
explained by mutations in BRCA1 and BRCA2 genes [10]
and other highly penetrant genes [11–13]. Despite the
increased risk in many cancers from a family history of
cancer, some studies suggest that family members may not
adhere to cancer prevention guidelines. For example, the
largest U.S.-based family cohort, the Sister Study [14],
found that only 12 % of women with a sister affected with
breast cancer adhere to all three guidelines [15]. Further, the
Sister Study found that there was substantial heterogeneity
in meeting these guidelines by women of different racial and
ethnic groups [15]. Specifically, they found that only 12.7 %
of white women and 4.5 % of black women met all three
guidelines (4.5 %) [15].
Given that adherence to cancer prevention guidelines
has been shown to substantially reduce mortality in aver-
age-risk cohorts (range of 27–42 % reduction in mortality),
we investigated whether this reduction in mortality from
meeting the ACS breast cancer guidelines holds in higher
risk populations in ethnically diverse women from our New
York Breast Cancer Family Registry. Specifically, we
examined the effect of adhering to ACS Guidelines for
breast cancer prevention in the United States, across white
and Hispanic women with a family history or personal
history of breast cancer. The recommendations include
adherence to physical activity (C150 min per week),
alcohol intake (B1 drink per day), and body mass index
guidelines (\25 kg/m2). We evaluated levels of adherence
with respect to all-cause mortality.
Materials and methods
The Breast Cancer Family Registry (BCFR), established in
1995, is a collaborative project with participants from six
research sites in the USA, Canada, and Australia [16]. For
this study, we included participants from the New York site
of the BCFR [17–19], a clinic-based site that identified
participants along with family members based on the fol-
lowing criteria: (1) a female with either breast or ovarian
cancer age 45 or less at diagnosis; (2) a male with a history
of breast cancer; (3) a female with a history of both breast
and ovarian cancer; (4) a female with one first-degree
relative or two second-degree relatives with a history of
either breast or ovarian cancer; (5) a family with a known
BRCA1 or BRCA2 mutation. We included women who
completed a baseline questionnaire, identified themselves
as either ‘White/Caucasian’ or ‘Hispanic/Latina’, and for
whom height, weight, physical activity, and alcohol intake
data were available. 1,000 women were affected with
breast cancer at enrollment (815 white, 185 Hispanic) and
1,905 women were unaffected relatives of those with breast
cancer (1,433 white, 472 Hispanic). For these analyses, we
examined women in two separate cohorts, those who were
affected with breast cancer at the time of baseline
(n = 1,000) and those who were unaffected women from
families with a history of breast cancer (n = 1,905). We
inlcuded outcomes through December 31, 2012, the end-
point for the start of analyses. The Institutional Review
Board of Columbia University Medical Center approved
the study and all participants provided informed consent.
We calculated BMI based on self-reported height and
weight at baseline [weight (kg)/height (m)2] and catego-
rized BMI according to ACS guidelines (\25 or C25 kg/
m2). We asked women to report their average hours per
week of moderate physical activity (e.g., brisk walking,
golf, volleyball, cycling on level streets, recreation tennis,
or softball) and strenuous exercise (e.g., swimming laps,
aerobics, calisthenics, running, jogging, basketball, cycling
on hills, racquetball) from the previous three years. We
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categorized physical activity (C150 or \150 min of mod-
erate or vigorous activity/week) to assess adherence to
ACS guidelines. Alcohol consumption per week in the last
3 years was self-reported and included details regarding
beer, wine or wine coolers, and hard liquor consumption.
We categorized alcohol consumption according to ACS
guidelines (B1 or [1 serving/day). We evaluated con-
founding based on data from the baseline questionnaire
including education (\high school, high school or voca-
tional tech, some college or graduate), age (continuous),
smoking status (never, former, current), history of mam-
mogram (yes, no), and hormone replacement therapy
(HRT) use (never, former, current) at baseline. We calcu-
lated the number of first- and second-degree family mem-
bers with breast cancer from self and relative reported
family history. We obtained vital status through self or
relative report at follow-up and matching of participants to
the National Death Index (NDI). In the analyses, we con-
sidered NDI-reported deaths if NDI assigned scores that
met recommended criteria [20].
We tested the associations between adherence to ACS
guidelines and all-cause mortality using Cox proportional
hazards models and tested for confounding by age at
baseline, education, smoking, number of relatives with
breast cancer, mammogram history, and HRT use through
a 10 % change in the beta coefficient for the categorical
constructs representing adherence. In addition, we assessed
interaction with race, age, and BRCA status through strat-
ified analyses and statistical tests of multiplicative inter-
action. We used adherence to 1 ACS recommendation as
the reference due to small samples in the 0 adherence
group. We used SAS 9.3 (SAS Institute, Cary, NC) to
conduct all statistical analyses.
Results
We included 2,905 women in this study, 2,248 white
women and 657 Hispanic women, and followed them for
an average of 9.17 ± 4.12 years during which time 312
deaths occurred. The mean age ± SD for white and His-
panic women was 50 ± 15.2 and 45 ± 15.2 years,
respectively. Compared to Hispanics, white women were
more likely to report some college degree or higher (86.0
vs. 38.1 %), were less likely to report being overweight or
obese (37.7 vs. 62.1 %), and were less likely to report
smoking or alcohol consumption (52.5 vs. 66.4 % and 45.8
vs. 72.7 %). White women were also more likely to be past
or current users of hormone replacement therapy (22.1 vs.
12.9 %). Fewer women in the affected cohort reported
never smoking compared to unaffected women (46.4 vs.
56.0 % in Whites and 62.2 vs. 68.0 % in Hispanics). As
expected, almost all the women who were affected with
breast cancer reported having had a mammogram, though
within the unaffected cohort white women were more
likely to have had a recent screening mammogram as
compared to Hispanic women (81.3 vs. 63.1 %). On
average, affected Hispanic women reported less exercise
than affected white women (3.7 vs. 4.6 h/week) (Table 1).
Approximately, half the women who were unaffected with
breast cancer at the time of enrollment adhered to the ACS
guidelines for physical activity and BMI \25 kg/m2. How-
ever, white women were more likely to exercise C150 min/
week (66.8 vs. 55.8 %) and were more likely to have a BMI
\25 kg/m2 (64.5 vs. 34.9 %) than Hispanic women. The
majority of unaffected women adhered with the alcohol con-
sumption guideline of \1 drink per day, though Hispanic
women were more adherent than white women (90.9 vs.
83.3 %). Overall, the majority of women in the unaffected
cohort did not adhere to all three of the ACS guidelines,
though white women were more likely to report adherence to
all three (36.2 vs. 17.6 %; p \ 0.001) (Table 2).
Women who were affected with breast cancer at the
time of enrollment had moderate adherence to the ACS
guidelines for physical activity and BMI \25 kg/m2.
However, white women were more likely to exercise
C150 min/week (62.0 vs. 42.7 %) and were more likely to
maintain a BMI \25 kg/m2 (57.8 vs. 34.1 %). White
women and Hispanic women who were affected with breast
cancer were equally adherent with the alcohol consumption
of \1 drink/day (86.0 and 86.0 %). Overall, women
affected with breast cancer were not adherent with ACS
guidelines. However, white women were more likely
to report adherence to all three recommendations (31.8 vs.
12.4 %; p \ 0.001) (Table 2).
After adjusting for age and education, we observed a
44–53 % reduction in rate of overall mortality in the
unaffected (HR 0.56; 95 %CI (0.33–0.93)) and affected
groups (HR 0.47; 95 %CI (0.30–0.74) (Table 3). We did
not observe confounding by the other factors considered
(age at baseline, education, smoking, number of relatives
with breast cancer, mammogram history, and HRT use).
The inverse associations with adherence and mortality
remained after stratification by age but the association was
only statistically significant in unaffected women
C50 years (HR 0.45; 95 % CI (0.24–0.84) and in affected
women \50 years [HR 0.19; 95 %CI (0.08–0.47); Fig. 1].
Adherence to all three guidelines was associated with a
27 % reduced mortality 95 % CI (0.28–1.89) in unaffected
women \50 years and 32 % reduced mortality 95 % CI
(0.41–1.12) in affected women [50 years. The inverse
association with adherence remained in all groups except
for unaffected Hispanic women, after stratification by race
and ethnicity (Table 3). Stratification by BRCA carrier
status showed that adherence to all three recommendations
was associated with a 61 % lower mortality [HR in
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Table 1 Participant characteristics at baseline for women in the NY site of the BCFR










Age (years) 46.7 ± 15.4 43.9 ± 16.1 0.001 55.9 ± 13.0 47.7 ± 12.4 \0.001
B35 362 (25.3) 149 (31.6) 0.029 22 (2.7) 20 (10.8) \0.001
36–45 353 (24.6) 122 (25.9) 165 (20.3) 75 (40.5)
46–55 331 (23.1) 85 (18.0) 244 (29.9) 53 (28.7)
56–65 201 (14.0) 64 (13.6) 197 (24.2) 17 (9.2)
[65 186 (13.0) 52 (11.0) 187 (22.9) 20 (10.8)
Education
\High school 16 (1.1) 170 (36.0) \0.001 10 (1.2) 63 (34.1) \0.001
High school or
vocational/tech
164 (11.4) 116 (24.6) 121 (14.9) 55 (29.7)
Some college or
graduate
1,251 (87.3) 183 (38.8) 683 (83.8) 67 (36.2)
Unknown 2 (0.1) 3 (0.6) 1 (0.1) –
Body mass index (kg/m2)
\18.5 50 (3.5) 16 (3.4) \0.001 19 (2.3) 1 (0.5) \0.001
18.5–24.9 874 (61.0) 169 (35.8) 452 (55.5) 62 (33.5)
25.0–29.9 336 (23.5) 180 (38.1) 234 (28.7) 75 (40.5)
C30 167 (11.7) 106 (22.5) 109 (13.4) 47 (25.4)
Unknown 6 (0.4) 1 (0.2) 1 (0.1) –
Smoking status
Never smoked 801 (56.0) 321 (68.0) \0.001 378 (46.4) 115 (62.2) \0.001
Past smoker 519 (36.2) 102 (21.6) 402 (49.3) 55 (29.7)
Current smoker 111 (7.8) 47 (10.0) 34 (4.2) 12 (6.5)
Unknown 2 (0.1) 2 (0.4) 1 (0.1) 3 (1.6)
Alcohol consumption
Never drank 649 (45.3) 346 (73.3) \0.001 380 (46.6) 127 (68.7) \0.001
Past drinker 245 (17.1) 51 (10.8) 153 (18.8) 37 (20.0)
Current drinker 528 (36.9) 71 (15.0) 278 (34.1) 19 (10.3)
Unknown 11 (0.8) 4 (0.9) 4 (0.5) 2 (1.1)
Female family members with breast cancer
0 148 (10.3) 61 (13.0) \0.001 171 (21.0) 93 (50.3) \0.001
1 458 (32.0) 239 (50.6) 301 (36.9) 46 (24.9)
2 492 (34.3) 101 (21.4) 184 (22.6) 28 (15.1)
C3 335 (23.4) 71 (15.0) 159 (19.5) 18 (9.7)
Ever had mammogram?
Yes 1,159 (81.0) 298 (63.1) \0.001 810 (99.4) 182 (98.4) 0.23**
No 266 (18.6) 168 (35.6) 3 (0.4) 2 (1.1)
Unknown 8 (0.6) 6 (1.3) 2 (0.3) 1 (0.5)
History of hormone replacement therapy
Never used 1,087 (75.9) 378 (80.1) \0.001 639 (78.4) 164 (88.7) \0.001**
Past use 118 (8.2) 45 (9.5) 138 (16.9) 13 (7.0)
Current use 210 (14.7) 25 (5.3) 31 (3.8) 2 (1.1)
Unknown 18 (1.3) 24 (5.1) 7 (0.9) 6 (3.2)
Mean ± SD (Q1,
median, Q3)
Mean ± SD (Q1,
median, Q3)
Mean ± SD (Q1,
median, Q3)
Mean ± SD (Q1,
median, Q3)
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carriers = 0.39; 95 % CI (0.16–0.97)]; adherence to all
three recommendations in non-carriers was associated with
a 50 % lower mortality [HR in non-carriers = 0.50;
95 %CI (0.36–0.70)] (Fig. 2).
Discussion
Women in our cohort who reported adherence to all three
ACS guidelines had a 44–53 % reduction in all-cause
mortality as compared with women who were only adhered
to one guideline. Only 3.0 % of our cohort reported not
adhering to any of the three ACS guidelines, which limited
separate analysis of this group. These results remained after
examining confounding by age at baseline, education,
smoking, number of relatives with breast cancer, mam-
mogram history, and HRT use. These results are also
consistent with other cohort studies with participants of
average risk including the European Prospective Investi-
gation into Cancer and Nutrition (EPIC) [3] where partic-
ipants who adhered to zero out of four health
recommendations had a four-fold increase in all-cause
mortality, as well as the Cancer Prevention Study II
Nutrition Cohort [8] and the Women’s Health Initiative [9]
which showed a 42 and 27 % reduction of all-cause mor-
tality, respectively, when comparing those most adherent to
American Cancer Society guidelines to those least
adherent.
Women with a first-degree relative with breast cancer
have a two-fold increased risk of developing breast cancer
in their lifetime [11], which is substantially higher based on
the ages of onset of the relatives. Although women with a
genetic mutation at the BRCA1 or BRCA2 gene are at
substantially higher lifetime risk, only 5–10 % of women
with a family history are carriers [21–24]. Women in our
cohort are at an overall higher risk than women in the
general population. Ten-year breast cancer risks observed
in this cohort were 7.03 % for women 35–49 years and
8.49 % for women 50 years and above; 3.1 times that of an
average-risk population when comparing to age-standard-
ized SEER rates [25]. Despite having a personal history of
breast cancer, only 28.2 % were adherent to all three
guidelines for physical activity, maintaining a healthy
BMI, and alcohol consumption and only 31.6 % of unaf-
fected women from families at high risk for breast cancer
were adherent to all three guidelines. While adherence was
low in our cohort, it should be noted that the majority of
women reported adherence with the recommendation for
one or less alcoholic beverage per day (85 %). The rates of
Table 1 continued












5.0 ± 4.6 (1.5, 3.5,
7.0)
4.6 ± 5.0 (0.0, 3.0,
8.0)
0.159* 4.6 ± 4.3 (1.0, 3.0,
6.5)
3.7 ± 4.8 (0.0, 1.5,
6.0)
0.018*
All values are n (%) or mean ± SD
Note negligible missing data for most variables (exercise hours per week had the highest at 4 %)
p value based on Chi-square
* p value based on t test
** p value based on Fisher’s exact test
Table 2 Women in the NY site of the BCFR without breast cancer at











922 (66.8) 250 (55.8) \.001
Meets BMI (\25 kg/m2)
recommendation




1,194 (83.3) 429 (90.9) \.001
Meets all three ACS
recommendations












485 (62.0) 76 (42.7) \.001
Meets BMI (\25 kg/m2)
recommendation




701 (86.0) 159 (86.0) 0.83
Meets all three ACS
recommendations
259 (31.8) 23 (12.4) \.001
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adherence were considerably lower for maintaining a
healthy BMI (57 %) and participating in physical activity
for at least 150 min each week (60 %). However, differ-
ences in reporting of these three constructs may affect
some of the adherence as measured.
Adherence was low across all subgroups, although white
women were more adherent with all three lifestyle behav-
iors combined as compared to Hispanic women (36.2 vs.
17.6 % in unaffected women; 31.8 vs. 12.4 % in affected
women). This same trend held for each of the individual
behaviors except for alcohol consumption. While white and
Hispanic women were equally adherent in the affected
cohort (86.0 vs. 86.0 %), white women were less adherent
than Hispanic women (83.3 vs. 90.9 %) in the unaffected
cohort. These results are consistent with other high-risk
cohorts. Spector et al. [15] showed that white and black
women who are sisters of women with breast cancer had
low adherence to recommendations for physical activity
(26.4 and 18.2 %, respectively) and maintaining a healthy
BMI (42.5 and 16.7 %, respectively). However, black
women were more likely to comply with ACS alcohol
recommendations [15]. A prospective cohort study by
Fig. 1 Multivariable models examining ACS adherence at baseline and overall survival by age in women at the NY site of the BCFR
Table 3 Multivariable models examining ACS adherence at baseline and overall survival in white and Hispanic women at the NY site of the
BCFR
Women without breast cancer at baseline Women with breast cancer at baseline
Age Adjusted Adjusted* Age Adjusted Adjusted*
HR 95 % CI HR 95 % CI HR 95 % CI HR 95 % CI
Among all women
ACS compliance
Adherent on 1 recommendation 1.00 1.00 1.00 1.00
Adherent on 2 recommendations 0.86 (0.57, 1.29) 0.85 (0.56, 1.28) 0.82 (0.54, 1.13) 0.89 (0.64, 1.24)
Adherent on 3 recommendations 0.55 (0.33, 0.90) 0.56 (0.33, 0.93) 0.42 (0.27, 0.64) 0.47 (0.30, 0.74)
Women without breast cancer at baseline Women with breast cancer at baseline
White Hispanic White Hispanic
HR 95 % CI HR 95 % CI HR 95 % CI HR 95 % CI
Stratified by race/ethnicity
ACS compliance
Adherent on 1 recommendation 1.00 1.00 1.00 1.00
Adherent on 2 recommendations 0.67 (0.43, 1.06) 2.3 (0.81, 6.59) 0.85 (0.59, 1.25) 1.01 (0.52, 1.96)
Adherent on 3 recommendations 0.48 (0.28, 0.81) 1.89 (0.34, 10.64) 0.5 (0.32, 0.81) 0.51 (0.14, 1.76)
*Adjusted for age and education
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Thomson et al. showed that cancer incidence, all-cause,
and cancer-specific mortality were reduced through
adherence to a greater number of ACS guidelines which
suggests that adherence to ACS recommendations can be
beneficial across all subgroups [9]. Furthermore this same
cohort [9] showed benefits from adherence in affected
women and all-cause mortality across racial and ethnic
subgroups; an important finding as many minority popu-
lations are often diagnosed at later stages of disease and
experience worse outcomes [26–29].
Breast cancer incidence, particularly for cancer with
distal involvement is increasing in young women
(\40 years) [30]. The increase is seen across all racial and
ethnic subgroups but the rate of increase is higher in non-
white women [31]. Both Hispanic and black women are
more likely to present at a later stage at the time of diag-
noses and have higher rates of breast cancer-specific
mortality than non-Hispanic white women [32]. The Sis-
ter’s Study indicates differences in adherence with cancer
prevention guidelines between white and black women
[15], and our data indicate that there are similar differences
between white and Hispanic women in adherence.
Continuing to urge clinicians to advise all patients and their
families to adhere to cancer prevention guidelines is an
obvious first step. However, our study along with the
existing evidence suggests that specific recognition and
solutions need to be addressed so that interventions can be
targeted to groups with the greatest need.
This large, prospective cohort is focused on women that
are higher risk for breast cancer from their family history.
Due to smaller numbers than some of the very large cohorts,
we were not able to consider cancer-specific mortality. As
we relied on self report, it is possible that women reported
adherence to the guidelines when in actuality they would not
have adhered. This would be non-differential misclassifi-
cation, however, as all participants from this cohort reported
their adherence at baseline without knowing their outcomes.
Therefore, associations may be even stronger than we esti-
mated if there are no large unmeasured confounders.
Although we were able to consider empirical confounding
by a number of factors, as our exposures were not ran-
domized it is possible that the effects observed would be
smaller if there are large, unmeasured, positive confounders.
Because the data for physical activity, alcohol consumption,
and body size were collected at baseline, we were also
unable to address whether adherence to these guidelines
later in life reduces mortality as it is possible that the women
who complied with the guidelines have been engaging in
healthy behaviors throughout their life.
For women not already meeting guidelines, clinical tri-
als focused on changing behaviors later in life support the
challenge of long-term maintenance of lifestyle changes
[33–35]. As research may indicate that behavior changes
later in life have a lower probability of being maintained,
families at high risk of breast cancer should be informed at
an earlier stage in life that making healthy behavioral
changes with respect to alcohol consumption, physical
activity, and maintaining a healthy weight have positive
benefits associated with a reduction in overall mortality
[36]. Breast cancer prevention, such as changes in these
reported lifestyle behaviors, are most likely to have the
greatest impact when initiated earlier in life and maintained
over the lifecourse [37].
The magnitude of the associations we observed was as
large as or larger than many other primary, secondary, and
tertiary breast cancer prevention interventions. For
Fig. 2 Multivariable models
examining ACS adherence at
baseline and overall survival by
carrier status in women at the
NY site of the BCFR
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example, mammography screening is associated with a
19 % reduction in mortality with a greater reduction in
mortality for screening over age 50 [38, 39]. Chemopre-
ventive medications have also been linked with reduced
risk in high-risk women as well as adjuvant treatment for
women with estrogen receptor-positive breast cancers in
the range of 31–67 % and a reduction in breast cancer
mortality of 30 % [40]. Our findings suggest a large
potential for reduced mortality from following these
guidelines. However, adherence to these behaviors is cur-
rently low in the general population [6] as well as in high-
risk cohorts [15]. Adherence across high-risk minority
groups is even lower [15]. Adherence to chemoprevention
and mammography screening, in contrast, is much higher
in high-risk cohorts with regular mammography screening
and five-year use of chemoprevention of tamoxifen with
40–83 % [41–44] and 41–72 % [45] adherence, respec-
tively. Thus, substantial gains can be made in primary,
secondary, and tertiary prevention in all women, and
especially those at higher risk, from improving adherence
with screening, chemoprevention, and alcohol, physical
activity, and body size guidelines.
Conclusion
In summary, we found that among women with a family or
personal history of breast cancer, adherence to all three
ACS breast cancer prevention guidelines for physical
activity, alcohol consumption, and maintaining a healthy
weight was associated with a reduction in mortality com-
pared to women who were only adherent to one guideline.
Even in white and Hispanic women with a family history of
breast cancer, adherence with the three cancer prevention
guidelines remained low. Substantial gains can be made in
prevention for women, especially those at high risk based
on family history, by improving adherence to these lifestyle
behaviors.
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